DiaMedica Therapeutics Inc.
Close on Oct 19, 2026
- Market cap
- $424.15M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | During market hours | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | During market hours | – | $-0.19 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 31, 2026 | During market hours | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | During market hours | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | During market hours | – | $-0.18 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | During market hours | – | $-0.18 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 17, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | During market hours | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 19, 2024 | During market hours | – | – | – |
Press releases
Announcements DiaMedica Therapeutics filed with the SEC
DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Results of operations · EX-99.1 to Form 8-K
DiaMedica Therapeutics Reports First Quarter 2026
Results of operations · EX-99.1 to Form 8-K
DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights
Results of operations · EX-99.1 to Form 8-K
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
Results of operations · EX-99.1 to Form 8-K
DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
Results of operations · EX-99.1 to Form 8-K
DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
DiaMedica Therapeutics Raises $30 Million in
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights
Results of operations · EX-99.1 to Form 8-K
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
DiaMedica Therapeutics Appoints Daniel J. O ’ Connor to the Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
DiaMedica Therapeutics Announces $11.8 Million
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
DiaMedica Therapeutics Provides a Business Update and
Results of operations · EX-99.1 to Form 8-K
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
DiaMedica Therapeutics Announces $37.5 Million Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke
Other events · EX-99.1 to Form 8-K
DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K